What is happening. Rifampin is hepatotoxic and silymarin from milk thistle is often taken for liver support; combining them can obscure or complicate interpretation of liver enzyme changes, and rifampin may reduce silymarin exposure through enzyme induction.
Mechanism. Rifampin induces CYP and UGT enzymes that conjugate silibinin, lowering its plasma exposure. Independently, rifampin can cause dose-dependent hepatotoxicity, so concurrent hepatoprotective supplement use may mask early biochemical warning signs.
Recommendation. If using milk thistle during rifampin therapy, continue routine liver function monitoring and do not interpret normal results as proof of liver safety. Report any signs of hepatotoxicity such as jaundice, dark urine, or right upper quadrant pain to a clinician.